- Lab-Grown Mini Organs Could Speed Up Drug Discovery (forbes.com)
The thought of lab-grown organs conjures up Frankenstein-like imagery. The reality however, is somewhat less visually dramatic, with the term ‘organoids’ used to describe tiny 3D structures of human tissue, a millimeter or so in diameter...these tiny lumps of cells are creating a lot of excitement in the world of medical research...Cells in dishes and animal models have been used for preclinical testing of drugs for decades. Success in these experiments is a key hurdle for any new medicine to overcome before being given the green light for all-important human clinical trials...Organoids are most commonly made either from a small sample of tissue needled out of a person or from stem cells cultured in a cocktail of nutrients intent on pushing them towards becoming a particular tissue type. So far, organoids have been made resembling several tissues including lung, liver, brain, kidney and intestine...as a relatively new innovation they are being used to investigate dozens of conditions from infectious diseases to cancer.... A study published last year in Science Translational Medicine by scientists at the University Medical Centre, Utrecht generated organoids formed from the rectal tissue of 71 people with cystic fibrosis and exposed them to experimental drugs. By observing changes in the organoids, the scientists accurately predicted which patients would respond to the therapies in just one week at a cost of around $1200 per patient. The results were so convincing that a positive organoid test is now considered sufficient evidence for insurance companies to fund the new therapies in the Netherlands...
- Eyeing big returns, drugmakers ready new hepatitis-C drug launches (mmm-online.com)
market for the new class of hepatitis-C drugs is becoming more crowded as a higher percentage of patients seek out therapies with shorter treatment durations and drugmakers pursue indications for more stubborn forms of the infection...
- Organ-on-a-chip startup Emulate raises $28.75M Series B (medcitynews.com)
Cambridge organ-on-a-chip startup Emulate has raised $28.75 million in a Series B round, with aims to commercialize its "Human Emulation System" on the R&D circuit. The idea, as with most lab-on-a-chip technologies, is to enhance in vitro research so as to make animal and in-human studies more efficient – using algorithms and microfluidics to accurately predict human response to medicines, chemicals and diseases...The financing will help expand Emulate’s organ-on-a-chip portfolio. Currently, it’s got organ emulations of the lung, liver, intestine and skin – but it plans to branch into organs like the kidney, heart and brain. Beyond that, however, is the concept of developing specific labs-on-chips to address important disease states, such as cancers, disorders of the intestine and microbiome, and infectious disease...Emulate wants its technology to operate as a plug-and-play system in the hands of product development teams at pharmaceutical, chemical, food and consumer products companies...
- The Future Of Medicine Might Be 3D-Printed Pills (itechpost.com)
Researchers from the University of Columbia, University of North Carolina, and Wake Forest University presented a 3D printer software that creates pills for patients. The software calculates the medicine's dosage based on the patient's medical and biological data…a prototype software that creates customized pills for patients. The software uses algorithms that enables it to adjust medical dosages based on patient information like weight, race, liver and kidney functions…In a trial run, the researchers created patient profiles that resulted in different dosages of 80 total pills printed. The pills ranged from 124 mg to 373 mg, which were dosages with high accuracy with little inconsistency.